DPP-4 inhibitors can minimize the hypoglycemic burden and enhance safety in elderly people with diabetes

Although more information is needed to reach definitive conclusions, growing evidence suggests that DPP4-I may become a valuable component in the pharmacologic management of elderly persons with T2DM (Diabetes, Obesity and Metabolism)